Literature DB >> 16707525

Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema.

C K M Chan1, S Mohamed, M P Shanmugam, C-W Tsang, T Y Y Lai, D S C Lam.   

Abstract

BACKGROUND/AIM: Intravitreal triamcinolone (IVTA) results in transient improvements in diabetic macular oedema (DMO), necessitating repeated injections. The authors report a case series of 10 eyes of 10 patients with DMO, who received a repeat injection of 4 mg IVTA, at least 26 weeks after the first injection of the same dose.
METHOD: Pre-injection and at 2, 4, 9, and 17 weeks post-injection, best corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography, after the first and repeat injections, were compared using paired t test. Side effects were monitored.
RESULTS: BCVA, CFT, intraocular pressure (IOP), and cataract scores were not significantly different before initial and repeat injections (given at 32.5 (SD 3.5) weeks after the first injection). Transient improvements of BCVA and CFT were achieved after both injections. However, after the repeat injection, the BCVA was significantly worse at all time points (p<0.05) and so were the best achieved CFT and the CFT at 4 weeks post-injection (p = 0.034 and 0.011 respectively), compared with the initial injection. Post-injection maximum IOPs and increase in cataract scores were not significantly different between the two injections.
CONCLUSION: A repeat injection of 4 mg of IVTA may not be as effective as an initial injection for the treatment of DMO.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707525      PMCID: PMC1857409          DOI: 10.1136/bjo.2006.093211

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  25 in total

1.  Transient improvement in visual acuity and macular edema in central retinal vein occlusion accompanied by inflammatory features after pulse steroid and anti-inflammatory therapy.

Authors:  S Shaikh; M S Blumenkranz
Journal:  Retina       Date:  2001       Impact factor: 4.256

2.  Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration.

Authors:  Jost B Jonas; Imren Akkoyun; Wido M Budde; Ingrid Kreissig; Robert F Degenring
Journal:  Arch Ophthalmol       Date:  2004-02

3.  Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.

Authors:  Paul M Beer; Sophie J Bakri; Ravinder J Singh; Weiguo Liu; George B Peters; Michael Miller
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

4.  Patterns of diabetic macular edema with optical coherence tomography.

Authors:  T Otani; S Kishi; Y Maruyama
Journal:  Am J Ophthalmol       Date:  1999-06       Impact factor: 5.258

5.  Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema.

Authors:  Ingrid U Scott; Harry W Flynn; Philip J Rosenfeld
Journal:  Am J Ophthalmol       Date:  2003-10       Impact factor: 5.258

6.  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1985-12

Review 7.  Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies.

Authors:  Thomas A Ciulla; Armando G Amador; Bernard Zinman
Journal:  Diabetes Care       Date:  2003-09       Impact factor: 19.112

8.  Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema.

Authors:  Jost B Jonas; Robert F Degenring; Bernd A Kamppeter; Ingrid Kreissig; Imren Akkoyun
Journal:  Am J Ophthalmol       Date:  2004-07       Impact factor: 5.258

9.  Tachyphylaxis to topical steroid measured by histamine-induced wheal suppression.

Authors:  G Singh; P K Singh
Journal:  Int J Dermatol       Date:  1986-06       Impact factor: 2.736

10.  The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group.

Authors:  L T Chylack; J K Wolfe; D M Singer; M C Leske; M A Bullimore; I L Bailey; J Friend; D McCarthy; S Y Wu
Journal:  Arch Ophthalmol       Date:  1993-06
View more
  7 in total

1.  Intravitreal triamcinolone for diffuse diabetic macular oedema.

Authors:  A Longo
Journal:  Br J Ophthalmol       Date:  2006-09       Impact factor: 4.638

2.  Combined triamcinolone acetonide injection and grid laser photocoagulation: a promising treatment for diffuse diabetic macular oedema?

Authors:  Tomohiro Iida
Journal:  Br J Ophthalmol       Date:  2007-04       Impact factor: 4.638

Review 3.  Statement of the German Ophthalmological Society, the German Retina Society, and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : Dated August 2019.

Authors: 
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

4.  Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema.

Authors:  Mark C Gillies; F M Amirul Islam; Meidong Zhu; Jorgen Larsson; Tien Y Wong
Journal:  Br J Ophthalmol       Date:  2007-04-03       Impact factor: 4.638

Review 5.  Clinical trials on corticosteroids for diabetic macular edema.

Authors:  Hassan A Al Dhibi; J Fernando Arevalo
Journal:  World J Diabetes       Date:  2013-12-15

6.  Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema.

Authors:  Ju Hwan Song; Jung Joo Lee; Sang Joon Lee
Journal:  Korean J Ophthalmol       Date:  2011-05-24

7.  Cost-effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: A Markov-model.

Authors:  Mari Pesonen; Eila Kankaanpää; Pasi Vottonen
Journal:  Acta Ophthalmol       Date:  2021-01-09       Impact factor: 3.761

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.